[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639094":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":24,"locations":24,"responsibleParty":41,"collaborators":24,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":24,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":24,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":24,"overallStatus":65,"whyStopped":24,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":24},{"fullName":5,"class":6},"Jiangmen Central Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Low-Dose Radiotherapy + EP\u002FEC + Adebrelimab","EXPERIMENTAL","All subjects will first receive low-dose radiotherapy (DT 15 Gy, 1.5 Gy per fraction × 10 fractions, BID). Within one week after radiotherapy completion, they will receive 4-6 cycles of systemic chemotherapy (EP or EC regimen) combined concurrently with adebrelimab. Following the 4-6 cycles of chemo-immunotherapy, adebrelimab maintenance therapy will be continued for two years.",[13,14,15,16,17],"Drug: Etoposide","Drug: Cisplatin","Drug: Carboplatin","Drug: Adebrelimab","Radiation: Thoracic Radiotherapy",[19,25,29,33,37],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Etoposide","Etoposide 100 mg\u002Fm² on days 1-3 plus cisplatin 25 mg\u002Fm² on days 1-3, every 3 weeks (q3w), or etoposide 100 mg\u002Fm² on days 1-3 plus carboplatin AUC 5 on day 1, every 3 weeks (q3w).",[9],null,{"type":20,"name":26,"description":27,"armGroupLabels":28,"otherNames":24},"Cisplatin","Etoposide (100 mg\u002Fm²) and cisplatin (25 mg\u002Fm²) were administered on days 1-3 of each 3-week cycle.",[9],{"type":20,"name":30,"description":31,"armGroupLabels":32,"otherNames":24},"Carboplatin","Etoposide (100 mg\u002Fm²) was given on days 1-3 and carboplatin (AUC 5) on day 1 of each 3-week cycle.",[9],{"type":20,"name":34,"description":35,"armGroupLabels":36,"otherNames":24},"Adebrelimab","20 mg\u002Fkg intravenously on day 1, repeated every 21 days (q3w). Administered concurrently with chemotherapy for 4-6 cycles, followed by maintenance monotherapy for up to 2 years.",[9],{"type":38,"name":39,"description":11,"armGroupLabels":40,"otherNames":24},"RADIATION","Thoracic Radiotherapy",[9],{"type":42,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","Lin Xiao","Deputy Director of the Oncology Department","100639094","phase-2-low-dose-thoracic-radiotherapy-followed-by-adebrelimab-plus-chemotherapy-and-then-sequential-maintenance-therapy-with-adebrelimab-for-extensive-stage-small-cell-lung-cancer-100639094",false,"NCT07583550","Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer","Efficacy and Safety of Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy and Sequential Adebrelimab Maintenance Therapy for Extensive-stage Small Cell Lung Cancer: A Prospective, Multicenter Phase II Study","Inclusion Criteria:\n\n1. Age ≥18 years and ≤75 years;\n2. Histologically or cytologically confirmed SCLC;\n3. No malignant pleural effusion or pericardial effusion;\n4. No prior history of thoracic radiotherapy or thoracic surgery;\n5. No prior systemic anti-tumor therapy;\n6. ECOG performance status 0-2, with a life expectancy of ≥12 weeks;\n7. At least one measurable lesion per RECIST 1.1 criteria;\n8. No history of interstitial pneumonia;\n9. No history of immune-related pneumonitis;\n10. No history of autoimmune diseases;\n11. No history of significant active pulmonary infection;\n12. No use of corticosteroid therapy within 14 days prior to enrollment;\n13. No Grade ≥3 hematologic toxicity or hepatic\u002Frenal impairment;\n14. No brainstem metastases and no significant neurological symptoms;\n15. For subjects with coexisting HBV\u002FHCV infection, hepatic impairment ≤ Grade 1 after prior active antiviral therapy;\n16. All subjects have provided written informed consent;\n\nExclusion Criteria:\n\n1. Presence of interstitial pneumonia or infectious fever prior to treatment;\n2. Comorbid autoimmune diseases or long-term oral corticosteroid use (including those who received oral corticosteroids within 14 days prior to treatment);\n3. Prior history of thoracic radiotherapy or thoracic surgery;\n4. Presence of Grade ≥3 hematologic toxicity or hepatic\u002Frenal impairment;\n5. Hypersensitivity to adebrelimab;\n6. Significant respiratory symptoms that preclude tolerance to radiotherapy;\n7. Active hepatitis B or C infection, currently on antiviral therapy, and with liver function impairment of Grade 2 or above;\n8. Presence of pleural effusion or pericardial effusion;","ALL","18 Years","75 Years",{"count":56,"type":57},43,"ESTIMATED","INTERVENTIONAL",[60],"PHASE2","This study is a multicenter, prospective investigation aiming to evaluate the efficacy and safety of low-dose radiotherapy (15Gy\u002F1.5 Gy bid × 10 fractions) combined with 4-6 cycles of systemic chemotherapy concurrently with Adebrelimab, followed by Adebrelimab maintenance therapy for up to two years, in subjects with extensive-stage small cell lung cancer (ES-SCLC). Additionally, immunohistochemical detection of the expression levels of four key transcriptional proteins-YAP1, NEUROD1, ASCL1, and POU2F3-will be performed to guide the molecular subtyping of SCLC. Based on these findings, we will explore the differential therapeutic outcomes of this regimen across distinct molecular subtypes (A\u002FN\u002FP\u002FY\u002FI\u002FAN\u002FQN), with the goal of identifying the subject population most likely to benefit from this treatment modality, thereby optimizing clinical decision-making.",[63,64],"Lung","Radiotherapy","NOT_YET_RECRUITING","2026-07-20",{"date":68,"type":69},"2026-07-22","ACTUAL",{"date":71,"type":57},"2026-07-21",{"date":73,"type":57},"2028-01-01",{"name":5,"class":6}]